Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United ...
VYJUVEK is a proprietary, non-invasive, redosable gene therapy platform designed to treat dystrophic epidermolysis bullosa (DEB). It utilizes an engineered, replication-defective, and non-integrating HSV-1 vector to deliver functional COL7A1 genes to the skin cells of patients, addressing the root cause of the disease at the genetic level.
Pain Points: Addresses the lack of treatment options for severe, life-threatening genetic skin diseases; provides a solution for chronic, recurring wounds that do not heal; offers a redosable mechanism to maintain therapeutic efficacy.
Solutions: Restores functional collagen type VII production, enables wound healing, and reduces the debilitating symptoms of fragile skin through a non-invasive, topical delivery system.
Target Users: Patients suffering from dystrophic epidermolysis bullosa and the medical professionals/hospitals specializing in rare skin disease management.
Supply Chain
In-house GMP manufacturing facilitiesProprietary viral vector production platformSpecialized cold-chain distribution networkClinical support partners and healthcare systems
